FDG-PET Trial
VIA completed a third Phase 2 clinical trial where patients who have had a recent heart attack underwent Positron Emission Tomography with flurodeoxyglucose tracer (“FDG-PET”), an experimental non-invasive imaging technique to measure the effect of treatment of VIA-2291 on uptake of FDG into the vascular wall.
The Phase 2 FDG-PET trial enrolled 52 patients into a 24 week randomized, double blind, placebo-controlled study. Endpoints in the study include assessment of FDG-PET into the vascular wall, as well as assessment of standard biomarker measurements of inflammation.